文献速递肝病消化道肿瘤与早癌

代谢功能障碍相关脂肪性肝病中肝细胞癌的新型风险预测模型:一项跨国多中心队列研究

A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-10

该多中心队列研究纳入韩国及其他亚洲和西方国家20个医学中心的77677例代谢功能障碍相关脂肪性肝病患者(2004—2023年),基于时间依赖Cox多变量分析在训练队列(n=36800,韩国)中开发出包含5个风险因素的MASLD-HCC评分,并在内部(n=36799,韩国)和外部(n=4078,11个其他亚洲和西方国家)验证。模型区分度良好且校准佳,高风险组肝细胞癌风险显著高于低风险组,作者认为该评分可帮助医生对肝细胞癌风险进行分层。

要点

  • 超重/肥胖或中心性肥胖及糖尿病前期/糖尿病与肝细胞癌发生独立相关。
  • MASLD-HCC评分含年龄、性别、血小板、肥胖指标和糖代谢状态5个因素。
  • 训练队列Harrell C指数0.84,内部验证0.83,外部验证0.93,校准良好。

核心结论

  • 超重/肥胖或中心性肥胖及糖尿病前期/糖尿病合并纤维化负担与MASLD患者肝细胞癌风险升高显著相关。
  • MASLD-HCC评分可能帮助医生对肝细胞癌风险进行分层。

研究设计与样本

  • 多中心队列研究,从韩国及其他亚洲和西方国家20个医学中心招募77677例MASLD患者(2004—2023年)。
  • 基于时间依赖Cox多变量分析在训练队列(n=36800,韩国)中开发MASLD-HCC评分,内部验证队列n=36799(韩国),外部验证队列n=4078(11个其他亚洲和西方国家)。

主要发现

  • 训练队列中71例(0.2%)发生肝细胞癌,中位随访5.1年。
  • 超重/肥胖或中心性肥胖、糖尿病前期/糖尿病与肝细胞癌发生独立相关,同时年龄、性别和血小板也相关。
  • MASLD-HCC评分的Harrell C指数在训练队列为0.84,内部验证队列为0.83,外部验证队列为0.93,模型校准良好。
  • 决策曲线分析显示患者从该模型获得正的净获益。
  • 按MASLD-HCC评分分层,高风险组肝细胞癌风险显著高于低风险组:训练队列sHR 11.44(95%CI 7.10-18.41),内部验证sHR 12.36(95%CI 7.72-19.79),外部验证sHR 56.84(95%CI 12.88-250.73),均P<.001。

关键数值与推荐

  • MASLD-HCC评分包含5个风险因素:年龄、性别、血小板、超重/肥胖或中心性肥胖、糖尿病前期/糖尿病。
  • 训练队列Harrell C指数0.84,内部验证0.83,外部验证0.93。
  • 高风险组vs低风险组肝细胞癌风险:训练队列sHR 11.44(95%CI 7.10-18.41),内部验证sHR 12.36(95%CI 7.72-19.79),外部验证sHR 56.84(95%CI 12.88-250.73),均P<.001。

临床怎么用

  • 作者认为MASLD-HCC评分可能帮助医生对MASLD患者的肝细胞癌风险进行分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is unclear that which cardiometabolic risk factors (CMRFs) are significantly associated with hepatocellular carcinoma (HCC) development in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to develop and validate a novel CMRF-based HCC risk prediction model in MASLD. METHODS: This multicenter cohort study recruited 77,677 MASLD patients from 20 medical centers in Korea and other Asian and Western countries (2004-2023). A novel CMRF-based HCC risk prediction model (MASLD-HCC score) was developed based on time-varying Cox multivariable analysis in a training cohort (n = 36,800, Korea), which was validated internally (n = 36,799, Korea) and externally (n = 4078, 11 other Asia and Western countries). RESULTS: In the training cohort, 71 (0.2%) patients developed HCC (median follow-up 5.1 years). Overweight/obesity or central obesity and prediabetes/diabetes were independently associated with HCC development, along with age, sex, and platelets. The MASLD-HCC score with these 5 risk factors showed a Harrell's C-index of 0.84 for HCC development, which was maintained in the internal (C-index 0.83) and external validation cohorts (C-index 0.93), and the model was well calibrated. Decision curve analyses showed that patients had positive net benefits from the model. When stratified by the MASLD-HCC score, the risk of HCC development in the high-risk group was significantly higher than the low-risk group (training: subdistribution hazard ratio [sHR], 11.44; 95% confidence interval [CI], 7.10-18.41; internal validation: sHR, 12.36; 95% CI, 7.72-19.79; external validation: sHR, 56.84; 95% CI, 12.88-250.73; all P < .001). CONCLUSIONS: Overweight/obesity or central obesity and prediabetes/diabetes with fibrotic burden were significantly associated with the increased HCC risk in MASLD. The MASLD-HCC score may enable physicians to stratify the HCC risk.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chun HS, Lee M, Lee HA, et al. A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 40645391. doi:10.1016/j.cgh.2025.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。